Abstract:Elicitation of antibodies with potent and broad neutralizing activity against HIV by immunization remains a challenge. Several monoclonal antibodies (mAbs) isolated from humans with HIV-1 infection exhibit such activity but vaccine immunogens based on structures containing their epitopes have not been successful for their elicitation. All known broadly neutralizing mAbs (bnmAbs) are immunoglobulin (Ig) Gs (IgGs) and highly somatically hypermutated which could impede their elicitation. Ig Ms (IgMs) are on average significantly less divergent from germline antibodies and are relevant for the development of vaccine immunogens but are underexplored compared to IgGs. Here we describe the identification and characterization of several human IgM-derived mAbs against HIV-1 which were selected from a large phage-displayed naive human antibody library constructed from blood, lymph nodes and spleens of 59 healthy donors. These antibodies bound with high affinity to recombinant envelope glycoproteins (gp140s, Envs) of HIV-1 isolates from different clades. They enhanced or did not neutralize infection by some of the HIV-1 primary isolates using CCR5 as a coreceptor but neutralized all CXCR4 isolates tested although weakly. One of these antibodies with relatively low degree of somatic hypermutation was more extensively characterized. It bound to a highly conserved region partially overlapping with the coreceptor binding site and close to but not overlapping with the CD4 binding site. These results suggest the existence of conserved structures that could direct the immune response to non-neutralizing or even enhancing antibodies which may represent a strategy used by the virus to escape neutralizing immune responses. Further studies will show whether such a strategy plays a role in HIV infection of humans, how important that role could be, and what the mechanisms of infection enhancement are. The newly identified mAbs could be used as reagents to further characterize conserved non-neutralizing, weakly neutralizing or enhancing epitopes and modify or remove them from candidate vaccine immunogens.

Preparation and characterization of four novel monoclonal antibodies specific to N51(L6)C46 polypeptide simulating fusogenic core structure of GP41 subunit of HIV-1.

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Hiv-1 Gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad Hiv-1 Neutralizing Antibodies

Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors

Characterization and epitope mapping of a panel of monoclonal antibodies against HIV-1 matrix protein.

[Expression, Structure and Antigenicity Analysis of N51 Derived from the N-terminal Heptad Repeat Domain in Gp41 of HIV-1 CRF07_BC Strain].

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.

Selection of a Novel Gp41-Specific HIV-1 Neutralizing Human Antibody by Competitive Antigen Panning.

[Preparation and Characterization of Monoclonal Antibody Against Gp120 V1/V2 Domain of HIV-1 Subtype CRF01_AE].

Isolation and Characterization of a Novel Neutralizing Antibody Targeting the CD4-binding Site of HIV-1 Gp120.

[Characterization of the HIV-1 Subunit Vaccine Containing the Gp41 NHR Domain of the HIV-1 CRF01_AE Recombinant Subtype in China].

Development of Two Potential Diagnostic Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein B

Cross-Reactive Human Igm-Derived Monoclonal Antibodies That Bind to Hiv-1 Envelope Glycoproteins

Three Candidate Peptide-Vaccines in Combination to Induce High Levels of Multiantibodies Against HIV-1

Human Immunodeficiency Virus Type 1 Gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection.

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1.

Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.

Isolation and functional identification of HIV-1 envelope specific monoclonal antibodies

A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.